BetterLife Closes $138.7M Offering, Faces Director Dispute Over $2M Convertible Debenture
BETRF has more than doubled off its 52-week low of $0.028.
Summary
BetterLife Pharma closed a $138.7M public offering on September 17, 2026, funding its BETR-001 clinical program, but disclosed a dispute with a director over a $2M convertible debenture and going concern language in its interim financials.
Key Events · Financing and Capital Events · BETRF
-
$138.7M Public Offering Closed
On September 17, 2026, BetterLife issued 447,041,840 common shares at $0.25 and 107,958,160 pre-funded warrants at $0.24999 for gross proceeds of $138,748,920. Agents' fees totaled $9,605,879 with 38,284,189 broker warrants issued at $0.25 exercise price expiring September 17, 2029.
-
Director Dispute Over $2M Convertible Debenture
Director Dr. Steven Sangha disputed the company's right to repay the $2,000,000 convertible debenture, returned the principal repayment on September 22, 2026, and issued a conversion notice. Both parties are seeking legal advice to resolve the remaining principal.
-
Going Concern Warning
At July 31, 2026, material uncertainty existed casting substantial doubt on the company's ability to continue as a going concern. The company had an accumulated deficit of $122,785,512 and working capital deficiency of $7,631,319.
-
Net Loss of $2.7M for Six Months
Net loss for the six months ended July 31, 2026 was $2,704,167, including a $771,902 non-cash warrant liability fair-value loss driven by the share price rising from US$0.038 to US$0.21 — not a cash outflow and not new dilution.
Analysis · BETRF · Life Sciences
A transformative $138.7 million public offering closed on September 17, 2026, with 447 million common shares issued at $0.25 and 108 million pre-funded warrants at $0.24999. For a company that held only $973,593 in cash at July 31, 2026 and carried a working capital deficiency of $7.6 million, this capital raise is pivotal. The proceeds fund the full Phase 1A/1B/2 clinical program for BETR-001, budgeted at $105 million. However, the filing also reveals a dispute with director Dr. Steven Sangha over the $2 million convertible debenture — he returned the principal repayment and issued a conversion notice, and both parties are seeking legal advice. The financial statements carry going concern language: material uncertainty existed at July 31, 2026 that casts substantial doubt on the company's ability to continue. The $771,902 warrant liability fair-value loss is a non-cash mark-to-market driven by the share price rising from US$0.038 to US$0.21 — not a cash outflow and not new dilution.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 40.6% of the 330 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BETRF was trading at $0.21 on OTC in the Life Sciences sector, with a market capitalization of approximately $127.9M. The 52-week trading range was $0.03 to $0.33. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.